Prospective Acid Reflux Study of Iran (PARSI): Methodology and study design

BMC Gastroenterology

Reza Malekzadeh¹  Shahnaz Tofangchiha¹  Mehdi Nouraie¹  Azadeh Mofid¹  Behnoush Abedi¹  Masoud Sotoudeh¹  Amir-Ali Sohrabpour¹  Pardis Mostajabi¹  Mohamad-Hamed Ghotbi¹  Mansoureh Mamarabadi¹  Seyed Maysam Alimohamadi¹  Hadi Razjouyan¹  Siavosh Nasseri-Moghaddam¹ 

[1]Digestive Disease Research Center (DDRC), Shariati Hospital, Medical Sciences/University of Tehran, North Kargar Ave., Tehran, Iran

Others  :  1211629
DOI  :  10.1186/1471-230X-7-42

 received in 2007-07-07, accepted in 2007-11-20,  发布年份 2007

【 摘 要 】

Background

Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce. This is especially prominent when looking at non-erosive reflux disease (NERD) patients.

Methods

We designed a prospective cohort to assess the long term outcome of GERD patients referring to gastroenterologists. Consecutive consenting patients, 15 years of age and older, presenting with symptoms suggestive of GERD referring to our outpatient clinics undergo a 30 minute interview. Upper gastrointestinal endoscopy is performed for them with protocol biopsies and blood samples are drawn. Patients are then treated according to a set protocol and followed regularly either in person or by telephone for at least 10 years.

Discussion

Our data show that such a study is feasible and follow-ups, which are the main concern, can be done in a fairly reliable way to collect data. The results of this study will help to clarify the course of various subgroups of GERD patients after coming to medical attention and their response to treatment considering different variables. In addition, the basic symptoms and biological database will fuel further molecular epidemiologic studies.

【 授权许可】

   
2007 Nasseri-Moghaddam et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton U 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997, 112(5):1448-56.
• [2]El-Serag HB, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease. Gut 1998, 43(3):327-33.
• [3]Dent J, El-Serag HB, Wallander M-A, Johansson S: Epidemiology of gastroesophageal reflux disease: A systematic review. Gut 2005, 54:710-717.
• [4]Nasseri-Moghaddam S, Malekzadeh M, Sotoudeh M, Tavangar M, Azimi K, Sohrabpour AA, Mostadjabi P, Fathi H, Minapoor M: Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol 2003, 18(3):5-21.
• [5]Nouraie M, Razjouyan H, Assady M, Malekzadeh R, Nasseri-Moghaddam S: Epidemiology of Gastroesophageal Reflux Symptoms in Tehran, Iran; a population-based Telephone Survey. Arch Iran Med 2007, 10(3):289-294.
• [6]Wicklund 1K, Glise H: Quality of life in different gastrointestinal conditions. Eur J Surg Suppl 1998, 582:56-61.
• [7]Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesopgaheal reflux disease, on health-related quality of life. Am J Med 1998, 104(3):252-8.
• [8]Armstrong D: Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999, 72(2–3):93-100.
• [9]Saidi F, Malekzadeh R, Sotoudeh M, Derakhshan MH, Farahvash MJ, Yazdanbod A, Merat S, Mikaeli J, R Sotoudehmanesh, Nasseri-Moghadam S, Majidpour A, Arshi S, Abedi-Ardakani B, Yoonessi A, Sadr F, Sepehr A, Fleischer D, Fahimi S: Endoscopic esophageal cancer survey in the western part of the Caspian Littoral. Diseases of the Esophagus 2002, 15:214-218.
• [10]Spechler SJ: Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992, 51(Suppl 1):24-9.
• [11]Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999, 106:642-49.
• [12]Galmiche JP, Bruley des Varannes S: Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994, 201:62-8. Review
• [13]Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998, 10(2):119-24.
• [14]Gerson LB, Shetler K, Triadafilopoulos G: Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002, 123(2):461-7.
• [15]Avidan B, Sonnenberg A, Schnell TG, Sontag SJ: Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002, 47(11):2565-73.
• [16]Lieberman DA, Oehlke M, Helfand M: Risk factors for Barrett's esophagus in community-based practice. GORGEconsortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997, 92(8):1293-97.
• [17]Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, Lapertosa G, Iaquinto G, Sablich R, Gusmaroli R, Aste H, Giacosa A: Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE) [Risk factors for Barrett's esophagus: a case-control study]. Int J Cancer 2002, 97(2):225-29.
• [18]Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985, 313(14):857-859.
• [19]Eisen G: The epidemiology of gastroesophageal reflux: what we know and what we need to know. Am J Gastroenterol 2001, 96(suppl):S16-18.
• [20]Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O: Natural course of gastroesophageal reflux disease: 17–22 year follow-up of 60 patients. Am J Gastroenterol 1997, 92:37-41.
• [21]McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH: Three to 4.5 year prospective study of prognostic indicators in gastrooesophageal reflux disease. Scand J Gastroenterol 1998, 33:1016-22.
• [22]Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek W, Stolte M, Vieth M, Willich S, Malfertheiner P: Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004, 99(9):1652-6.
• [23]Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999, 45(2):172-80.
• [24]Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20(10):1161-81. Review
• [25]Tofangchiha S, Razjouyan H, Ghotbi MH, Nouraie M, Alimohammadi M, Mamarabadi M, Nasrollahzadeh D, Didar L, Mofid A, Malekzadeh R, Nasseri-Moghaddam S: Validation of the Quality of Life In Reflux and Dyspepsia (QOLRAD) Questionnaire in Patients with Iranian patients with GERD [abstract]. Govaresh 2006, 11:s28.
• [26]Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B: The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005, 14:875-882.